EGFR mutations in lung cancer: From tissue testing to liquid biopsy

Francesca Fenizia, Antonella De Luca, Raffaella Pasquale, Alessandra Sacco, Laura Forgione, Matilde Lambiase, Alessia Iannaccone, Nicoletta Chicchinelli, Renato Franco, Antonio Rossi, Alessandro Morabito, Gaetano Rocco, Maria Carmela Piccirillo, Nicola Normanno

Research output: Contribution to journalArticlepeer-review


The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.

Original languageEnglish
Pages (from-to)1611-1623
Number of pages13
JournalFuture Oncology
Issue number11
Publication statusPublished - Jun 1 2015


  • EGFR mutations
  • liquid biopsy
  • mechanisms of resistance
  • non-small-cell lung carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'EGFR mutations in lung cancer: From tissue testing to liquid biopsy'. Together they form a unique fingerprint.

Cite this